Unprecedented global attention to social and environmental issues, and their implications for health and wellbeing, are driving new, transformative ideas of what constitutes value, risk, transparency and enterprise. While there have always been socially minded investors, the last decade has seen huge momentum to meet the global demand for positive social impact.
Our commitment to positive social impact
At Endeavour Vision we are taking this global opportunity seriously. We are a UNPRI (United Nations Principle for Responsible Investment) signatory, reporting annually on our progress at every stage of the investment process towards responsible investing. In 2021, we published the first impact analysis of our EMG II fund that looks at the clinical, healthcare and societal impact of portfolio companies and their technologies.
We believe that medical innovation can improve the standard of care for millions of people, positively impact patients’ wellbeing and bring efficiency and innovation to global health systems. As the world’s population ages and healthcare budgets strain to keep pace with mounting costs, healthcare innovations can support the achievement of the UN Sustainable Development Goals (SDGs), including SDG3 – Good health and well-being, SDG8 – Decent work and economic growth, SDG9 – Industry, innovation and infrastructure and SDG5 – achieving gender equality and empowering all women and girls.
Learn how our portfolio company Willow is making it easier through its technology, for women to transition back to work after maternity leave and, at the same time, supporting them to continue breastfeeding.
Our approach to ESG and responsible investing
At Endeavour Vision, our holistic approach in taking an investment decision begins at the pre-investment stage (screening, deep dive and due diligence processes), and includes investment criteria such as whether an opportunity addresses significant unmet medical needs, offers superior clinical outcomes and innovative solutions, and benefits the patient. We also consider its impact on reducing healthcare costs and streamlining healthcare systems. At the post-investment stage, Endeavour Vision encourages the leadership of its investment companies to consider and raise material Environmental, Social and Governance (ESG) issues that they might encounter. We have also introduced an ESG analysis that will help to identify potential ESG issues and provide guidance to investment companies on how to address these and improve their ratings each year.
As board members for most of the companies we invest in, we are able to actively engage and support our investment companies to achieve their milestones and ensure they have appropriate policies and company culture in place to do so.
If you would like to learn more about our approach to responsible investing, or would like to receive a copy of our Impact Analysis of EMG II portfolio companies, please contact us.
Read about our approach to sustainability risk management here
Testimonials
“ Endeavour Vision is an extremely thorough and thoughtful healthcare investor, and at Virtual Incision we sincerely value and appreciate their Series C support. EV brings domain knowledge and a global perspective to help us pioneer the use of mini-robots for abdominal procedures — great partners to have around our board table.”
John Murphy, CEO, Virtual Incision Corporation“As a trusted Board Member and Partner, Endeavour Vision brings a wealth of operational and financial experience to the team. They are interested in building companies the right way and creating a foundation for long-term accelerated growth, through a collaborative and detailed approach. Endeavour has always been a positive influence on our company and market. They are not only interested in representing transformational technologies but ensuring those technologies bring significant benefit to patients across the globe.”
Christopher M. Owens, President & CEO, Gynesonics “Endeavour Vision became our preferred partner to enter our next growth stage for a multitude of reasons. Aside from the deep level of expertise in HealthTech overall and their long-term perspective on creating sustainable change in the sector, we really valued the strong involvement of senior experts from the get go. As a result, the due diligence questions were sharp, challenging and to the point, which allowed us to dive into deep strategic conversations fast. Lastly, we simply clicked with the great team on a professional and personal level, who share the same passion to re-invent a much needed space.”
Katrin Alberding and Clemens Raemy, Co-CEOs, Kenbi“We find in Endeavour Vision a unique and highly-sophisticated team, which adds significant value to our commercialization ramp-up. This includes strategic input, organisational development and talent acquisition. They’re an investment team which works closely with management to identify creative solutions to complex issues, leading the maximum value creation for the enterprise. I highly recommend Endeavour Vision as a valuable venture partner.”
Earl R.Fender, Previously President & CEO, Vertiflex; CEO, Nalu“We are delighted to have Endeavour Vision as our partner on Willow’s mission of building solutions to moms’ most meaningful problems. They bring deep passion for our work; robust and relevant industry insights; excellent connections; and they ask outstanding, perceptive questions that help us ensure we’re thinking about and tackling the most important topics.”
Laura Chambers, CEO, Willow“As the founding investor in CeQur, Endeavour Vision has been an invaluable partner over the years, providing strategic input, on-going support and financing. I’ve enjoyed getting to know several members of the team, each bringing their own unique expertise, and all committed to our success. In the world of healthcare technology investors, you’d be hard pressed to find a better partner.”
Bradley Paddock, CEO, CeQur Corporation“Endeavour Vision is a trusted and highly effective global thought partner who believes in building a company the right way. Operationally the Endeavour Vision team has broad skill sets including product development, regulatory science, clinical execution, and product launches to help achieve our mutual vision of providing a safe and effective transformational therapy that becomes the standard of care for patients worldwide.”
Dennis Wahr, CEO, Nuvaira“Endeavour Vision has been an invaluable investor in IntelyCare and a crucial partner to us in exceeding our high-growth goals and empowering healthcare heroes. Endeavour’s team has helped us identify key growth opportunities and has provided the capital needed to execute. From expanding our network of nursing professionals to building out our platform to help partnered facilities, Endeavour Vision’s leadership has been key to our rapid and sustained growth.”
David Coppins, CEO, IntelyCare“Endeavour Vision’s team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360˚ due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is “smart money” at its best.”
Jaques R. Essinger, former CEO, Symetis “From our introductory meeting, through the diligence and investment process and now as an active board member, the Endeavour Vision team has been a great partner. The team brings deep insights and a pragmatic approach to assisting high growth companies across a broad array of disciplines. Moreover, the team is a pleasure to work with and we look forward to our great partnership with Endeavour Vision as we continue to grow globally.”
Robert Spignesi, CEO, Rapid Micro Biosystems